{"id":"ekb-569","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Rash"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"EKB-569 works by selectively binding to the ATP-binding site of the EGFR tyrosine kinase, thereby inhibiting the enzyme's activity and blocking the downstream signaling pathways that promote cell proliferation and survival.","oneSentence":"EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:36:49.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00098501","phase":"PHASE1","title":"CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":42},{"nctId":"NCT00072748","phase":"PHASE2","title":"Study Evaluating EKB-569 in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms","enrollment":63},{"nctId":"NCT00067548","phase":"PHASE2","title":"Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung, Lung Neoplasms","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EKB-569","genericName":"EKB-569","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}